Ipsen ends neurotoxin pact with Galderma after arbitration cases filed in international court

Ipsen has ter­mi­nat­ed a 2014 neu­ro­tox­in R&D deal with Gal­der­ma af­ter the part­ner start­ed two cas­es at the In­ter­na­tion­al Cham­ber of Com­merce against Ipsen, the com­pa­ny said in its earn­ings state­ment Wednes­day.

Ipsen CEO David Loew said on a me­dia call that the com­pa­ny let Gal­der­ma know about the ter­mi­na­tion on Wednes­day night. The com­pa­ny plans to “ful­ly de­fend and vin­di­cate its rights” in the ICC cas­es, the com­pa­ny said in a state­ment. Ipsen CFO Aymer­ic le Chate­lier said the ar­bi­tra­tion is ex­pect­ed to fin­ish by the end of the year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN